The purpose of the study is to evaluate whether the novel anti-cancer drug OXY111A is safe and tolerated in patients with primary and secondary hepato-pancreato-biliary and gastrointestinal neoplasia as measured by exploring the maximum tolerated dose (MTD). At level of MTD, additional patients will be included aimed for assessing the efficacy profile in these neoplasia entities.

Start Date01 Feb 2014

Sponsor / Collaborator

University of Zurich

100 Clinical Results associated with Myoinositol Trispyrophosphate

100 Translational Medicine associated with Myoinositol Trispyrophosphate

100 Patents (Medical) associated with Myoinositol Trispyrophosphate

Literatures (Medical) associated with Myoinositol Trispyrophosphate

12 Dec 2024·Cureus

A Phase III, Double-Blind, Randomized, Multicenter, Clinical Trial to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Metformin Hydrochloride and Myo-Inositol Compared to Metformin in Patients With Polycystic Ovary Syndrome

Article

Author: Malvi, Abhijeet ; Srivastava, Shalini ; Singh, Purnima ; Kantha G, Lakshmi ; Shah, Sushma ; Maini, Neha ; Singh, Taruna ; Kriplani, Alka ; Paul, Joydip ; Kaitala, Shymala ; Bhatara, Urvashi ; Sinha, Archana ; Tank, Parikshit

Background Polycystic ovary syndrome (PCOS) poses a significant health concern among reproductive-aged women and is characterized by ovarian dysfunction, hyperandrogenism, and insulin resistance. This study aims to assess the efficacy and safety of metformin and myo-inositol combination therapy compared to metformin monotherapy in patients with PCOS. Materials and methods This was a phase III, double-blind, randomized controlled clinical trial. A total of 196 patients with PCOS were randomized in a 1:1 ratio to receive either a fixed-dose combination of metformin hydrochloride 500 mg and myo-inositol 600 mg (Met-Myo) or metformin 500 mg alone (Met) twice daily for 24 weeks. The primary study endpoints were improvement in insulin resistance (homeostatic model assessment of insulin resistance, HOMA-IR) at week 24 and improvement in menstrual cycle disturbances at 12 and 24 weeks. Results The Met-Myo combination demonstrated a significantly superior response with 63 (75%) patients showing improvement in HOMA-IR compared to 54 (60.67%) in the Met group (p = 0.049) at week 24. The improvement in the number of patients with heavy menstrual blood flow (>80 mL) was significantly greater in the Met-Myo group (four patients, 4.76%) compared to the Met group (six patients, 6.74%) at week 24 (p = 0.029). Improvement in the percentage of patients with normal menstrual frequency and infrequent menstruation from baseline to week 24 was significantly greater in the Met-Myo group compared to the Met group (p = 0.049). Safety assessments revealed a low and comparable incidence of mild adverse events. Conclusion Metformin-myo-inositol combination therapy is superior to metformin monotherapy in addressing menstrual irregularities and improving insulin resistance in PCOS patients, thereby providing a promising avenue for optimizing the management of PCOS.

01 Oct 2024·British Journal of Pharmacology

Myo‐inositol trispyrophosphate prevents right ventricular failure and improves survival in monocrotaline‐induced pulmonary hypertension in the rat

Article

Author: Torbicki, Adam ; Surzykiewicz, Mateusz ; Grzanka, Małgorzata ; Rolski, Filip ; Zajda, Karolina ; Zambrowska, Zuzanna ; Piekiełko‐Witkowska, Agnieszka ; Mączewski, Michał ; Kurzyna, Marcin ; Paterek, Aleksandra ; Kieda, Claudine ; Oknińska, Marta

AbstractBackground and PurposePulmonary hypertension (PH) results from pulmonary vasculopathy, initially leading to a compensatory right ventricular (RV) hypertrophy, and eventually to RV failure. Hypoxia can trigger both pulmonary vasculopathy and RV failure. Therefore, we tested if myo‐inositol trispyrophosphate (ITPP), which facilitates oxygen dissociation from haemoglobin, can relieve pulmonary vasculopathy and RV hypoxia, and eventually prevent RV failure and mortality in the rat model of monocrotaline‐induced PH.Experimental approachRats were injected with monocrotaline (PH) or saline (control) and received ITPP or placebo for 5 weeks. Serial echocardiograms were obtained to monitor the disease, pressure‐volume loops were recorded and evaluated, myocardial pO2 was measured using a fluorescent probe, and histological and molecular analyses were conducted at the conclusion of the experiment.Key Results and ConclusionsITPP reduced PH‐related mortality. It had no effect on progressive increase in pulmonary vascular resistance, yet significantly relieved intramyocardial RV hypoxia, which was associated with improvement of RV function and reduction of RV wall stress. ITPP also tended to prevent increased hypoxia inducible factor‐1α expression in RV cardiac myocytes but did not affect RV capillary density.ImplicationsOur study suggests that strategies aimed at increasing oxygen delivery to hypoxic RV in PH could potentially be used as adjuncts to other therapies that target pulmonary vessels, thus increasing the ability of the RV to withstand increased afterload and reducing mortality. ITPP may be one such potential therapy.

16 Sep 2024·Drug testing and analysis

Evaluating the Effects of Solid-Phase Cartridge Chemistry on Extraction of Bisphosphonates and ITPP From Equine Plasma.

Article

Author: Kennan, Lauren ; Hochwallner, Travis ; Richards, Stacey ; Klingberg, Joshua ; Keledjian, John

Bisphosphonate drugs and myo-inositol trispyrophosphate are of concern to the racing industry and have been listed as prohibited substances in equine sports. The current bisphosphonate plasma screening analysis employed at the Australian Racing Forensic Laboratory involves the use of sequential solid-phase extraction procedures, passing the samples through a mixed mode cartridge, followed by a weak anion exchange cartridge. The eluates collected following the second extraction are then methylated and analysed by liquid chromatography-mass spectrometry. Under these extraction conditions, some bisphosphonates have shown poor recovery. To improve the extraction efficacy, the effects of cartridge chemistry were evaluated. In particular, the weak anion exchange cartridges used for screening were compared to an affinisep AttractSPE polymeric phase cartridge. The effectiveness of each extraction approach was assessed through both a visual comparison of signal to noise in extracted chromatograms and recovery measurements to determine the best approach for routine screening.

100 Deals associated with Myoinositol Trispyrophosphate

External Link

KEGG	Wiki	ATC	Drug Bank
-	Myoinositol Trispyrophosphate	-	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Infertility	Phase 3	-	Biosearch SA	01 Feb 2016
Polycystic Ovary Syndrome	Phase 3	-	Biosearch SA	01 Feb 2016
Bile Duct Neoplasms	Phase 3	CH	University of Zurich	01 Feb 2014
Colorectal Cancer	Phase 3	CH	University of Zurich	01 Feb 2014
Hepatocellular Carcinoma	Phase 3	CH	University of Zurich	01 Feb 2014
Pancreatic Cancer	Phase 3	CH	University of Zurich	01 Feb 2014
Heart Failure	Phase 3	US	NormOxys, Inc.	-
Neoplasms	Phase 3	US	NormOxys, Inc.	-
Obesity	Phase 3	-	University of Zurich	-
Heart Failure	Discovery	-	University of Zurich	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02528526 (Pubmed \| Nat Commun) Manual	Phase 1	Neoplasms	28	Myo-inositol trispyrophosphate	(pkywypkxyp) = 32 treatment-related toxicities (mostly hypercalcemia) blfxikkrzt (hzesszxmjk )	Positive	21 Jun 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Myoinositol Trispyrophosphate

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation